WAP
ZYNE

Wealthcare Advisory Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Wealthcare Advisory Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-145
Closed -$1K – 2003
2021
Q1 		$1K Buy
+145
New +$657 ﹤0.01% 2043
2020
Q2 		– Sell
-145
Closed -$1K – 1448
2020
Q1 		$1K Hold
145
– – ﹤0.01% 1453
2019
Q4 		$1K Buy
+145
New +$992 ﹤0.01% 1358

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthcare Advisory Partners's ZYNE Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2021, closing a stake of 145 shares — an estimated $1K sold.

Wealthcare Advisory Partners first reported a position in ZYNE in Q4 2019 and held it in 3 quarters. The position peaked at $1K in Q1 2021. 65 funds tracked by Wall St. Rank hold ZYNE as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 145 Zynerba Pharmaceuticals, Inc shares in Q2 2021, an estimated $1K.
  • Wealthcare Advisory Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2019 and held it in 3 quarters.
  • Wealthcare Advisory Partners's Zynerba Pharmaceuticals, Inc position peaked at $1K in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.